NCT07385248尚未招募1 期
An Open-label, Randomized, 2-treatment, 2-sequence, 2-period, Crossover Study to Evaluate the Pharmacokinetics and Safety Between the Administration of AD-229 and the Administration of AD-2291 for Healthy Adults in Fasting State
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 入组人数
- 28
- 主要终点
- Maximum concentration of drug in plasma (Cmax)
研究概览
简要总结
The study compare and evaluate the safety and pharmacokinetic characteristics between the administration of AD-229 and the administration of AD-2291 in healthy adults.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 19 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Body mass index (BMI) between 18.5 kg/m2 and 29.9 kg/m2 at the time of screening visit
- •The Age equal to or greater than 19 in healthy volunteers at the time of screening visit
排除标准
- •Participation in another clinical study with an investigational drug within the 6 months from scheduled first administration
- •Other exclusions applied
研究组 & 干预措施
Sequence A
Experimental
Period 1 : Reference Drug(AD-2291), Period 2 : Test Drug(AD-229)
干预措施: AD-2291 (Drug)
Sequence B
Experimental
Period 1 : Test Drug(AD-229), Period 2 : Reference Drug(AD-2291)
干预措施: AD-229 (Drug)
Sequence B
Experimental
Period 1 : Test Drug(AD-229), Period 2 : Reference Drug(AD-2291)
干预措施: AD-2291 (Drug)
Sequence A
Experimental
Period 1 : Reference Drug(AD-2291), Period 2 : Test Drug(AD-229)
干预措施: AD-229 (Drug)
结局指标
主要结局
Maximum concentration of drug in plasma (Cmax)
时间窗: pre-dose (0hour) to 72hours
Cmax of AD-229
Area under the plasma concentration-time curve during dosing interval (AUCt)
时间窗: pre-dose (0hour) to 72hours
AUCt of AD-229
次要结局
未报告次要终点
研究者
相似试验
招募中
1 期
Compare and Evaluate the Safety and PK Data of a Single Dose Administration of 'AD-115A' or 'AD-1151'Gastric UlcerNCT07385235Addpharma Inc.46
已完成
1 期
Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-383 0.5/10/1000mg in Healthy VolunteersType 2 DiabetesNCT07304700Chong Kun Dang Pharmaceutical30
已完成
1 期
Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-383 0.25/12.5/1000mg in Healthy VolunteersType 2 DiabetesNCT07304726Chong Kun Dang Pharmaceutical30
已完成
1 期
Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-383 0.5/25/1000mg in Healthy VolunteersType 2 DiabetesNCT07304687Chong Kun Dang Pharmaceutical31
Enrolling By Invitation
1 期
Compare the Pharmacokinetics, Pharmacodynamics, Safety and Immunogenicity of SAL023 and Italy-Manufactured Evenity in Healthy SubjectsOsteoporosisNCT07384104Shenzhen Salubris Pharmaceuticals Co., Ltd.118